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The	 interactions	 either	 among	cells	 or	 among	
cells	and	components	of	the	extracellular	matrix	are	
very	important	in	the	maintenance	of	epithelial	cells	
structure	and	control	of	cell	growth	and	differentiation.	
They	are	mediated	by	adhesion	molecules	which	are	
involved	in	the	processes	of	embryogenesis,	morpho­
genesis,	normal	growth	and	development,	leukocyte	
extravasation,	blood	coagulation,	wound	healing,	 in	
signal	 transduction	as	well	as	 inflammation,	cancer	
invasion	and	metastasis	 [1,	 2].	Class	of	 adhesion	
molecules	comprises	the	major	 families:	cadherins,	
integrins,	 immunoglobulin	gene	superfamily,	selec­
tins	and	CD44	[3–5].	The	intercellular	adhesion	mole­
cule­1	(ICAM­1)	is	a	member	of	the	immunoglobulin	
gene	 superfamily	 of	 adhesion	molecules	mainly	
expressed	 in	 leukocytes	[6],	endothelial	cells	[7],	 in	
certain	types	of	epithelial	cells	[8]	and	fibroblasts	[9].	
ICAM­1	possesses	five	extracellular	Ig­like	domains,	
one	transmembrane	segment	and	a	short	cytoplas­
mic	tail	as	presented	in	Figure	[10].	Human	ICAM­1	
has	 five	extracellular	 Ig­like	domains	 [6–10].	Each	
of	 these	domains	presents	different	 ligand	specifi­
ty;	 for	example	 the	 lymphocyte	 function	associated	
antigen­1	(LFA­1)	antigen	is	found	to	prefer	the	first	
Ig	domain	[11],	whereas	the	Mac­1	binds	to	the	third	
domain	of	the	extracellular	part	of	the	molecule.	The	
first	Ig	domain	also	harbours	the	binding	site	for	major	
group	human	rhinoviruses	(HRV)	and	P. falciparum­
infected	erythrocytes.
ICAM-1 IN HEAD AND NECK CANCER
The	variable	binding	ability	of	the	ICAM­1	is	directly	
related	to	the	multifunctional	physiologic	and	biologic	
role	of	this	molecule.	The	participation	of	ICAM­1	in	
inflammatory	processes	and	in	migration	of	activated	
leukocytes	 in	 inflammatory	 foci	was	 first	 studied	 in	
the	skin	 [12,	13]	and	 is	 today	well	established.	This	
is	a	complex	process	mediated	by	several	adhesive	
molecules	expressed	both	on	the	leukocyte	and	en­
dothelial	membrane.	ICAM­1	is	also	known	as	a	potent	
costimulatory	molecule	in	T­cell	mediated	cytotoxicity	
[14];	the	contribution	of	this	adhesive	molecule	to	the	
host’s	immune	response	led	to	the	suggestion	that	the	
derangement	of	the	ICAM­1	expression	could	also	be	
correlated	to	the	cancerous	process,	as	cancer	is	in	
fact	a	cascade	of	reactions	closely	connected	to	the	
loss	of	normal	immune	surveillance.	Derangement	in	
the	architectural	structure	of	the	ICAM­1	or	significant	
alterations	in	the	concentration	of	its	soluble	form	has	
been	positively	related	to	breast	cancer	[15],	hema­
tologic	malignancies	[16,	17],	gastrointestinal	cancer	
[18]	and	melanoma	[19].	The	head	and	neck	cancer	is	
today	a	field	of	intense	research	worldwide.	The	evolu­
tion	of	diagnostic	methods	and	therapeutic	techniques	
has	failed	to	ameliorate	the	prognostic	indexes	of	the	
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Figure. Structure	of	 ICAM­1	and	binding	sites	 for	 the	main	
ligands	of	the	molecule
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disease	during	the	last	three	decades.	New	molecules	
are	constantly	sought	in	the	endless	armamentarium	
of	molecular	biology,	in	an	attempt	to	contribute	to	the	
diagnosis	of	the	disease	and	establish	novel	prognos­
tic	tools.	In	the	particular	case	of	ICAM­1,	the	study	of	
this	molecule	in	relation	to	cancer	presents	a	distinct	
advantage:	as	a	soluble	form	of	the	protein	circulates	
in	 human	serum,	commercially	 available	Enzyme­
Linked	 Immunosorbent	Assay	 (ELISA)	 kits	 can	be	
used	to	estimate	the	concentration	instead	of	the	more	
complicated	immunostaining	methods	which	are	also	
dependent	on	surgical	therapies	[20].	The	idea	of	a	
novel	molecular	index	easily	estimated	from	the	serum	
of	the	patient	before	and	after	therapeutic	approach	
has	pushed	the	research	efforts	mainly	towards	the	
direction	of	the	circulating	form	of	the	molecule.
Although	the	term	“head	and	neck”	cancer	includes	
every	neoplasm	developing	 in	 the	certain	anatomic	
region,	 the	most	common	use	of	 this	specific	 term	
is	 related	 to	 the	head	and	neck	squamous	cell	car­
cinoma,	covering	more	than	90%	of	these	tumours.	
Based	on	 the	knowledge	 that	 ICAM­1	 is	one	of	 the	
natural	 ligands	to	the	LFA­1	molecule	expressed	on	
leukocytes,	and	also	 to	a	suggested	association	of	
this	intracellular	adhesion	molecule’s	increased	serum	
levels	to	malignancy	[21],	many	researchers	attempted	
to	study	the	role	of	ICAM­1	in	squamous	carcinoma	
of	the	head	and	neck.	In	assays	concerning	cultured	
cell	 lines,	 it	 seems	 that	 ICAM­1	expression	 varies	
greatly	in vitro	from	one	experiment	to	another	[22].	
This	variability,	 sometimes	considered	as	 the	 result	
of	culture	conditions	 influence	makes	 it	difficult	 to	
determine	its	importance	as	a	marker	on	tumor	cells	
[23].	In	oral	squamous	cell	carcinoma	the	circulating	
ICAM­1	was	not	found	to	be	elevated	in	sera	of	patients	
compared	to	sera	of	normal	controls	[24],	although	in	
a	small	(n	=	22)	specimen	of	patients	with	laryngeal	
carcinoma,	a	statistically	 significant	decrease	was	
noted	 [25].	 To	 further	 complicate	 things,	 another	
study	shows	a	strong	positive	correlation	between	
increased	levels	of	soluble	ICAM­1	in	sera	of	patients	
suffering	from	laryngeal	cancer	and	healthy	controls	
mainly	regarding	the	advanced	stages	of	the	disease	
[26].	The	research	in	this	field	is	still	in	the	begining,	
nevertheless	 the	known	 interaction	of	 ICAM­1	with	
fibrinogen	of	 the	extracellular	matrix	 factor	hyaluro­
nan	excites	the	interest	for	further	elucidation	of	the	
role	of	this	molecule	in	dissemination	and	metastasis	
of	squamous	cell	carcinoma	 [27].	Still,	 the	 ICAM­1	
seems	to	be	absent	 in	normal	epidermal	cells;	as	 it	
is	mainly	expressed	 in	 leukocytes	and	endothelial	
cells,	 it	 is	suggested	that	the	possible	useful	 imple­
mentations	of	 the	developing	knowledge	about	 this	
molecule,	will	originate	from	the	study	of	neoplasms	
of	non­squamous	origin.	The	head	and	neck	is	also	
a	common	anatomic	site	for	the	appearance	of	ma­
lignancies	of	lymphic	tissue,	mainly	Hodgkin	disease	
and	non­Hodgkin	 lymphomas.	The	nasopharyngeal	
carcinoma	is	also	a	well­studied	tumor	characterised	
by	both	a	squamous	and	a	lymphic	component.	Over­
expression	of	the	ICAM­1	in	specimens	of	malignant	
tissue	combined	with	 increased	serum	 levels	of	 the	
soluble	form	were	detected	in	Hodgkin	disease	[28]	
usually	firstly	identified	as	nodal	disease	of	the	head	
and	neck	or	mediastinum.	Regarding	the	non­Hodgkin	
lymphomas	of	the	head	and	neck,	the	variable	forms	
of	this	disease	and	the	multiple	possible	cells	of	origin	
make	the	extraction	of	conclusions	an	arduous	task.	It	
appears		that	the	serum	ICAM­1	levels	are	associated	
with	poor	prognosis	of	this	malignant	entity;	in	addition	
the	normalisation	of	the	soluble	ICAM­1	levels	follow	
the	complete	 remission	of	 the	disease,	whereas	a	
new	increase	of	this	molecule	concentration	in	serum	
is	noted	in	relapses	[29].	A	novel	molecular	marker,	
demonstrating	 the	progression	of	 head	and	neck	
non­Hodgkin	lymphoma	may	arise	from	these	efforts,	
reflecting	essentially	 the	 shedding	of	 intercellular	
adhesion	molecules	from	damaged	endothelial	cells	
or	lymphoma	cells	into	serum	in	the	angiodestructive	
lymphoreticular	region	of	the	tumor.	These	conclusions	
are	also	confirmed	in	studies	concerning	other	ana­
tomic	sites	of	the	non­Hodgkin	malignancies	[30,	31]	
as	the	non­Hodgkin	lymphoma	is	a	haematologic	entity	
mainly	characterised	by	a	systemic	appearance.
The	nasopharyngeal	 carcinoma	 is	 a	malignant	
tumor	of	the	upper	respiratory	tract	with	an	 interes­
ting	pathologic	appearance,	 as	mentioned	above,	
a	combination	of	 lymphoid	and	epithelial	elements.	
Although	 rare	 in	 the	western	world,	 this	neoplasm	
is	very	 common	 in	 south­eastern	 Asia,	mainly	 in	
Chinese	population	where	a	genetically	determined	
predisposition	is	known	to	exist.	The	research	in	this	
direction,	 in	a	starting	point	yet,	still	has	some	chal­
lenging	 results	 to	demonstrate:	 it	 seems	 that	 the	
ICAM­1	concentration	shows	a	significant	elevation	
in	the	sera	of	patients	with	nasopharyngeal	carcinoma	
compared	 to	healthy	controls	and	compared	 to	pa­
tients	suffering	 from	 the	squamous	origin	 laryngeal	
and	oral	cancer	[25].	The	usefulness	of	the	intercel­
lular	adhesion	molecules	as	molecular	markers	in	the	
lymphoid	 tissue	neoplasms	coming	dimly	 into	sight	
today,	could	easily	 lead	 to	 the	hypothesis	 that	 the	
above	results	are	an	outcome	strongly	associated	to	
the	 lymphoid	element	of	the	disease.	Although	pro­
bably	a	simplified	statement,	 this	hypothesis	could	
direct	 the	 further	 research	efforts	 concerning	 the	
ICAM­1	more	towards	nasopharyngeal	carcinoma	than	
the	head	and	neck	squamous	cell	carcinoma.	To	this	
direction,	the	increased	levels	of	soluble	ICAM­1	were	
found	to	correlate	with	recurrence	and	poor	prognosis	
of	nasopharyngeal	carcinoma	 [32].	The	exact	 role	
of	these	adhesion	molecules	in	the	genesis	and	dis­
semination	of	the	disease	is	still	unknown;	a	possible	
association	of	ICAM­1	with	the	TATE	phenomenon	(tu­
mor	associated	tissue	eosinophilia)	which	appears	in	
nasopharyngeal	cancer,	was	found	to	be	a	misleading	
idea	[33]	whereas	a	relation	of	the	ICAM­1	decrease	to	
the	Epstein	—	Barr	virus	genome	commonly	detected	
in	NPC	is	still	under	investigation.	A	main	axis	in	this	
latter	field	is	that	an	increased	expression	of	ICAM­1	
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in	Epstein	—	Barr	positive	malignant	cells	may	be	
related	to	the	loss	of	the	host’s	immunosurveillance	
leading	 to	 the	progress	 and	dissemination	of	 the	
disease	 [34].	A	group	of	 latent	membrane	proteins	
encoded	by	 the	Epstein	—	Barr	 virus	genome	and	
expressed	in	nasopharyngeal	carcinoma	cells	seem	
to	be	associated	to	the	overexpression	of	intercellular	
adhesion	molecules	 in	 the	cellular	membrane	 lead­
ing	 to	 the	change	of	 the	adhesive	properties	of	 the	
above	cells	[35].	In	particular,	the	Ebstein	—	Barr	virus	
genome	is	almost	ubiquitously	identified	in	a	certain	
type	of	nasopharyngeal	carcinoma,	the	undifferentia­
ted	nasopharyngeal	carcinoma	(U­NPC)	or	lympho­
epithelioma	counting	 for	a	high	proportion	of	 these	
tumours.	In	this	NPC	subtype,	the	overexpression	of	
ICAM­1	in	neoplastic	cells	is	suggested	to	have	a	role	
in	the	recruitment	of	lymphocytes	intratumorally	[36]	
leading	to	the	characteristic	histological	appearance	
of	the	neoplasm:	a	prominent	inflammatory	infiltrate	
rich	in	lymphocytes.	Interestingly,	a	similar	mechanism	
connected	to	 the	overexpression	of	 the	 intercellular	
adhesion	molecule	in	basal	epithelial	cells	of	the	crypts	
of	palatine	tonsils	seems	to	characterise	the	intraepi­
thelial	lymphocytes	migration	during	inflammation	of	
these	tissues	[37].
The	cancer	of	the	thyroid	gland	is	also	a	promis­
ing	field	concerning	the	use	of	soluble	 ICAM­1	as	a	
molecular	index	in	serum.	Much	different	in	histologic	
patterns	 than	 the	other	neoplasms	of	 the	head	and	
neck,	this	malignancy	appears	in	four	major	clinico­
pathologic	 types:	 the	papillary,	 follicular,	anaplastic	
and	myeloid	carcinoma.	An	upregulation	of	soluble	
ICAM­1	in	thyroid	cancer	patients	comparing	to	nor­
mal	controls	 independently	of	 the	cancer	 type	was	
demonstrated	 in	a	study	[38],	and	the	same	results	
where	confirmed	in	another	study	limited	to	a	patient	
group	suffering	from	the	papillary	form	of	the	disease	
[39]	whereas	the	apical	surface	of	the	thyroid	papillary	
carcinoma	cell	is	found	to	have	the	main	expression	
of	 ICAM­1	by	 immunohistochemical	means	 [40].	
Early	studies	of	the	molecular	mechanisms	of	these	
phenomena	have	correlated	the	intercellular	adhesion	
molecule’	s	upregulation	in	thyroid	cancer	to	the	func­
tion	of	the	protein	kinase	pathway	(PKP)	suggesting	
that	this	physiologic	pathway	has	an	important	role	in	
the	progress	and	dissemination	of	thyroid	cancer	[41].	
Although	in	the	starting	point	yet,	the	soluble	ICAM­1	
seems	to	have	many	chances	to	be	established	as	a	
useful	marker	for	the	evaluation	of	thyroid	malignan­
cies.	Because	of	 the	many	different	histologic	and	
clinical	properties	of	 this	neoplasm	comparing	with	
the	other	malignancies	of	the	head	and	neck,	a	further	
reference	is	out	of	the	intention	of	this	mini­review.
The	 rare	malignancies	of	 the	head	and	neck	are	
reasonably	secondary	research	targets.	Nevertheless	
studies	in	some	tumours	with	unique	characteristics	
may	help	the	generalization	of	some	main	conclusions	
or	may	give	birth	to	new	research	pathways.	One	such	
tumour	is	the	adenoid	cystic	carcinoma	of	the	head	and	
neck,	characterised	by	a	slow	but	relentless	progres­
sion	over	a	number	of	years,	a	late	recurrence	and	a	
high	rate	of	distant	metastastic	foci.	In	this	malignancy,	
an	immunohistochemically	detected	downregulation	
was	found	to	coexist	with	increased	incidence	of	late	
distant	metastasis	and	poor	prognosis	[42].	In	another	
study,	the	up­regulation	of	ICAM­1	displayed	signifi­
cant	relationship	to	the	adenoid	cystic	carcinoma	with	
metastatic	lymph	node	or	local	recurrence	[43].	The	
rareness	of	 these	 tumors	and	controversial	 results	
from	another	study	regarding	the	role	of	the	ICAM­1	
molecule	in	adenoid	cystic	carcinoma	[44]	make	any	
conclusion	precarious.	 It	 should	also	be	mentioned	
that	a	higher	level	of	soluble	ICAM­1	was	closely	as­
sociated	with	impaired	T­cell	dependent	immune	func­
tions	assessed	by	delayed­type	hypersensitivity	skin	
reactions,	and	with	the	relapse	of	a	rare	non­Hodgkin	
lymphoma	named	lethal	midline	granuloma	[29]	ap­
pearing	as	an	efficient	parameter	for	the	monitoring	
and	evaluation	of	the	disease	course.
The	adhesion	molecules	are	today	the	focus	of	the	
scientific	interest	worldwide.	The	numerous	members	
of	this	group	are	under	investigation	for	their	partici­
pation	in	cell	adhesion,	inflammation	and	cancer.	Be­
cause	of	the	continuously	arising	information	about	the	
importance	of	role	of	these	molecules	in	physiologic	
and	pathophysiologic	processes	of	the	human	body,	
we	believe	that	a	review	of	the	current	literature	con­
cerning	each	of	these	molecules	would	be	a	challeng­
ing	essay,	valuable	for	the	researcher	and	therefore,	
worth	while.	In	particular,	ICAM­1	is	a	member	of	the	
immunoglobulin	adhesion	molecules	superfamily	with	
multiple	possible	useful	implementation	in	diagnosis	
and	clinical	evaluation	of	head	and	neck	cancer.	Many	
parameters	still	have	 to	be	clarified	concerning	 this	
molecule;	 the	present	studies	are	 few,	usually	with	
small	samples,	whereas	the	co­participation	of	many	
other	factors	makes	thorny	the	illumination	of	its	role	
in	the	neoplasmatic	process.	It	seems	therefore,	that	
ICAM­1	will	play	a	leading	part	in	the	research	of	can­
cer	in	the	forthcoming	years	interesting	and	valuable	
tools	for	the	diagnosis	and	prognosis	of	head	and	neck	
cancer	will	hopefully	ensue	from	these	efforts.
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РОЛЬ МОЛЕКУЛЫ МЕЖКЛЕТОЧНОЙ АДГЕЗИИ ICAM-1 
ПРИ РАКЕ ГОЛОВЫ И ШЕИ
Молекулы межклеточной адгезии (ICAM-1), ��л���ие�� ��одуктом гена �� члена �у�е��емей�т�а гено� иммуногло�улино�,         
эк���е��и�о�аны � клетках многих тканей чело�ека и ��инима�т уча�тие � ��де физиологиче�ких и �атофизиологиче�ких 
��оце��о�. В мини-о�зо�е о�о��ены �о�ледние данные до�ту�ной лите�ату�ы о� изменении у�о�н� эк���е��ии ICAM-1 
��и �аке голо�ы и шеи, а также о��уждены �озможно�ти ��именени� знаний о молекулах адгезии � о�ла�ти диагно�тики 
и ��огноза за�оле�ани�.
Ключевые слова: молекулы адгезии, молекула межклеточной адгезии ICAM-1, �ак �ото�ой �оло�ти, �ак голо�ы и шеи.        
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